Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

ClinicalTrials.gov ID: NCT03119467

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03119467. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 4:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas

Study identification

NCT ID
NCT03119467
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Enrollment
21 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 11, 2017 (Actual)
Primary completion
Nov 29, 2019 (Actual)
Completion
Dec 19, 2019 (Actual)
Last update posted
Dec 27, 2019

2017 – 2019

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35294-3300 —
City of Hope Duarte California 91010 —
University of Colorado Aurora Colorado 80045 —
University of Michigan Ann Arbor Michigan 48109 —
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
Utah Cancer Specialists Salt Lake City Utah 84106 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03119467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 27, 2019 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.